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Tobacco smoking is a leading cause of non-communicable disease globally and is a major risk factor for cardiovascular disease (CVD) and
lung disease. Importantly, recent data by the World Health Organizations (WHO) indicate that in the last two decades global tobacco use
has significantly dropped, which was largely driven by decreased numbers of female smokers. Despite such advances, the use of e-ciga-
rettes and waterpipes (shisha, hookah, narghile) is an emerging trend, especially among younger generations. There is growing body of evi-
dence that e-cigarettes are not a harm-free alternative to tobacco cigarettes and there is considerable debate as to whether e-cigarettes
are saving smokers or generating new addicts. Here, we provide an updated overview of the impact of tobacco/waterpipe (shisha) smok-
ing and e-cigarette vaping on endothelial function, a biomarker for early, subclinical, atherosclerosis from human and animal studies. Also
their emerging adverse effects on the proteome, transcriptome, epigenome, microbiome, and the circadian clock are summarized. We
briefly discuss heat-not-burn tobacco products and their cardiovascular health effects. We discuss the impact of the toxic constituents of
these products on endothelial function and subsequent CVD and we also provide an update on current recommendations, regulation and
advertising with focus on the USA and Europe. As outlined by the WHO, tobacco cigarette, waterpipe, and e-cigarette smoking/vaping
may contribute to an increased burden of symptoms due to coronavirus disease 2019 (COVID-19) and to severe health consequences.
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Introduction
‘Tobacco is a legal drug that kills many of its users when used exactly
as intended by manufacturers’. That is the beginning sentence of the
World Health Organizations (WHO) global report on trends in to-
bacco smoking from 2015.1 Indeed, in 2019, the WHO announced
that tobacco (i.e. tobacco cigarettes, pipes, cigars, waterpipes, smoke-
less tobacco products, and heated tobacco products, but not e-ciga-
rettes) kills up to half of its users and more than 8 million people each
year, of which 7 million are the result of direct tobacco use, while ex-
posure to second-hand smoke accounts for 1.2 million deaths among
non-smokers.2 Thus, the tobacco epidemic represents one of the big-
gest threats for public health as a major but also entirely preventable
cause of cardiovascular morbidity and mortality (summarized in
Figure 1). Recent data indicate that in the last two decades global to-
bacco use has dropped from 1.397 billion in 2000 to 1.337 billion in
2018, which was largely driven by decreased numbers of female
smokers (a decline of around 100 million).2 The WHO projects for
the first time a decline of more than 1 million male smokers by 2020
compared to 2018.2
Despite such advances, the use of e-cigarettes and waterpipe
products (shisha, hookah, narghile) is an emerging trend, especially
among younger generations. The misperception that these products
are substantially less harmful than tobacco cigarettes or even repre-
sent healthier alternatives, provides an explanation for this trend.3
The claim of being less harmful, the availability of countless ‘appealing’
flavours and the lack of regulations after their introduction to the
broader market make e-cigarettes and waterpipe products an at-
tractive gateway drug for adults and adolescents who have not previ-
ously smoked. Consequently, the number of e-cigarette and
waterpipe users has dramatically increased, with e-cigarettes being
the most commonly used smoking products in 2014 in the USA (>9-
fold increase in usage from 2011 to 2015) and a projected global sales
volume of US$26.84 billion by 2023.4–6 Also the prevalence of life-
time waterpipe use is of concern, ranging from 2.1% to 44.0% in the
USA, 11.6% to 40.1% in the UK, and 20.0% to 28.9% in Germany.7 As
a consequence, the USA recently announced a countrywide ban on
flavoured e-cigarettes, which may also include the ban of flavoured
waterpipe tobacco in the future, following the lead of other countries
with a strict prohibition of the use and sale of e-cigarettes (see last
sections for details).8
The mechanisms leading to cardiovascular diseases (CVDs) and
mortality in smokers are multifactorial and not fully understood.
Impaired endothelial function is an early pathophysiological biomark-
er in cigarette smokers as shown in 1993 by Celermajer et al.9
Importantly, endothelial dysfunction has been shown to be an early
critical event in the pathogenesis of most CVD.10,11 In this review, we
will discuss the current state of literature on how smoking and/or
vaping induces endothelial dysfunction and atherogenesis with focus
on tobacco cigarettes, e-cigarettes, and waterpipe.
Graphical Abstract
2 T. Münzel et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartj/article-abstract/doi/10.1093/eurheartj/ehaa460/5861975 by M
edical C
enter Library user on 08 July 2020
Figure 1 Hazard/odds ratio (HR/OR) or adverse effects (percentages) for smoking or vaping associated health risks or complications based on
selected representative studies. All alphabetical cross references in this figure (a, b, c. . .) are linked to literature reference numbers in the figure legend
that can be found in the Supplementary material online with exactly identical numbering. Stroke source reports: a165 (þþþ), b166 (þ), and c167 (þþ).
Perceived addictiveness source reports: d168 (þþ). Percentages refer to the proportion of participants (PP) who believe that smoking/vaping is addictive.
Chronic obstructive pulmonary disease (COPD) source reports: e169 (þþ), f170a (þþþ), and g170b (þþ) Myocardial infarction source reports: h,171
i,172 and j173 (þþ). Peripheral endothelial dysfunction source reports: k94 (þ) and l143 (þ). Percentages denote (k) relative difference in flow-mediated
dilation (FMD) of the brachial artery in response to acute tobacco cigarette and e-cigarette use and (l) relative decrease in arterial forearm blood
flow (FBF) in response to acute waterpipe smoking. Coronary artery disease source reports: m174 (þþþ), n175 (þþ), and o173 (þþ). Lung cancer source
reports: p176 (þþþ) and q177 (þþþ). Arterial stiffness source reports: r178a (þ) and s178b (þ). Percentages denote relative increase in augmentation
index (AIx) measured by tonometry in response to chronic tobacco cigarette and e-cigarette use or acute waterpipe smoking. Erectile dysfunction
source reports: t179 (þþþ). NA means not available. þ means medium (single cohort study <1000 subjects), þþ means good (single cohort study
>1000 subjects) and þþþ means strong (large scale meta-analysis) clinical evidence. Open access source for body image can be found at Pixabay
(https://pixabay.com/de/photos/anatomie-mann-mensch-körper-haut-254129/). Note of caution: The presented values are based on selected repre-
sentative studies with different quality levels of evidence highlighting the need for more research.
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Physiology and prognostic
implications of endothelial function
The endothelium is fundamental in the regulation of vascular tone, in-
flammation, vascular growth, platelet aggregation, and coagula-
tion.10,11 The endothelium produces important vasodilators with
anti-atherosclerotic and antiaggregatory properties such as nitric
oxide (•NO) and prostacyclin. Endothelial dysfunction (impaired bio-
chemical pathways in endothelial cells) is a characteristic feature of
coronary artery disease,12 and a predictor of atherosclerosis13 and
future cardiovascular events.14 Endothelial dysfunction is associated
with traditional cardiovascular risk factors such as age, smoking, dia-
betes mellitus, hyperlipidaemia, genetic predisposition, and arterial
hypertension.10,11 Endothelial dysfunction in humans is mostly meas-
ured by flow-mediated dilation (FMD) in the forearm, a technique
where the reinitiated blood flow after occlusion (ischaemia) for some
minutes causes endothelial •NO formation and vasodilation by mech-
anical and reoxygenation-mediated stimuli (called hyperaemia).15
Although the underlying pathophysiological mechanisms of endothe-
lial dysfunction are likely to be multifactorial, an increased production
of reactive oxygen species (ROS) within the vascular wall by systems
such as the nicotinamide adenine dinucleotide phosphate oxidase,
xanthine oxidase, the mitochondrial electron transport chain, and
uncoupled endothelial nitric oxide synthase (eNOS) are thought to
contribute to this phenomenon.10,11,16 The extremely fast, diffusion-
limited reaction of •NO with superoxide leads to formation of the
highly reactive oxidant peroxynitrite (ONOO-), that has vasocon-
strictive and cytotoxic effects, causing oxidative damage to proteins,
lipids, and DNA. Oxidative degradation of •NO by superoxide,
uncoupling of eNOS and tyrosine nitration/inactivation of prostacyc-
lin synthase are three particular examples of how oxidative stress
impairs endothelial function.
(Toxic) compounds in tobacco
cigarette smoke, e-cigarette
vapour, and waterpipe smoke
The literature on toxic compounds found in tobacco cigarette
smoke, e-cigarette vapour, and waterpipe smoke is vast. Here, we
present only the most important toxic components (summarized in
Table 1), while a detailed overview can be found in the
Supplementary material online. Some basic facts on heat-not-burn
tobacco products (e.g. iQOS), their regulation and data on their tox-
icity were reviewed previously17 and more details can be found in the
Supplementary material online.
....................................................................................................................................................................................................................
Table 1 Toxic compounds in smoke from tobacco cigarettes and waterpipe, and vapour from e-cigarettes (all referen-
ces in this table can be found in the Supplementary material online with exactly identical numbering)
Toxic compound type Toxic compound Concentration range
cigarette
Concentration range
e-cigarette
Concentration range
waterpipe
Carbonyls Formaldehyde 7–10 lg/puff2,32,180 0.12–82 mg/puff181–184 0.21–0.65 mg/puff185,186
Acetaldehyde 50–140 lg/puff2,32,180 0.2–53 mg/puff181–184 2.0–5.5 mg/puff185,186
Acrolein 6–14 lg/puff2,32,180 0.12–3.3 mg/puff181–184,187 0.06–1.19 mg/puff185,186
Propionaldehyde 0.4–5.9 mg/puff2,32,180 0.057–1.79 mg/puff181,182 0.05–1.06 mg/puff185,186
Crotonaldehyde 1–2 lg/puff2,32,180 ND–0.04 mg/puff188 0.78–1.39 mg/puff189
N-Nitrosamines N0-Nitrosonornicotine (NNN) 0.5–370 ng/puff2,32,180 ND–0.029 ng/puff22,183,190 0.2 ng/puff185,191
N0-Nitrosoanabasine (NAB) ND–15 ng/puff2,32,180 ND–0.01 ng/puff22,190 0.05 ng/puff185,191
4-(Methylnitrosamino)-1-(3-pyridyl)-
1-butanone (NNK)
1.2–77 ng/puff2,32,180 ND–0.019 ng/puff22,183,190 0.27 ng/puff185,191
N0-nitrosoanatabine (NAT) 0.8–16 ng/puff2,32,180 ND–0.085 ng/puff22,190 0.6 ng/puff185,191
VOCs Toluene 0.8–6.9 mg/puff2,32,180 ND–1.53 mg/puff192 0.058 mg/puff185,193
Benzene 0.6–4.5 mg/puff2,32,180 ND–0.41 mg/puff192 1.58 mg/puff185,193
Inorganic compounds Nickel ND–60 ng/puff2,32,180 0.1–6.4 ng/puff194 9.9 ng/puff185,195
Cobalt 0.013–0.02 ng/puff2,32,180 0.05–0.58 ng/puff196 0.7 ng/puff185,195
Chromium 0.4–7 ng/puff2,32,180 0.05–9 ng/puff194 13.4 ng/puff185,195
Lead 3.4–8.5 ng/puff2,32,180 0.16–3.8 ng/puff197 68.7 ng/puff185,195
Carbon monoxide (CO) 1–2.3 mg puff2,32,180 not applicable 1.15–1.67 mg/puff40,185,186
PAHs Benz[a]anthracene 2-7 ng/puff2,32,180 Not applicablea 1.3–1.6 ng/puff40,185,191
Benzo[b þ k]fluoranthene 1–3.4 ng/puff2,32,180 Not applicablea 0.13–2.16 ng/puff40,185,191
Benzo[a]pyrene 2–4 ng/puff2,32,180 Not applicablea 0.78–1.79 ng/puff40,185,191
Dibenzo[a, h]anthracene 0.06–0.4 ng/puff2,32,180 Not applicablea 0.86–ng/puff40,185,191
Nicotine 0.1–0.3 mg/puff2,32,180 0–0.142 mg/puff196 0–0.058 mg/puff185,186,198
Particulate matter TPM 0.1–1.7 mg/puff32 0.87–5.8 mg/puff199,200,b 1.8–9.3 mg/puff40,198,201
PAHs, polycyclic aromatic hydrocarbons and heterocyclic aromatic hydrocarbons; VOCs, volatile organic compounds.
aOnly a few studies find concentrations of PAHs in e-cigarette vapour that are close to the limit of quantification.
bLiquid aerosol droplets.
4 T. Münzel et al.
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Nicotine is the main reason why humans consume tobacco ciga-
rettes and their alternatives. This alkaloid is known to increase blood
pressure and heart rate, but it can also cause FMD due to the
increased cardiac output.18 Effects of nicotine have been controver-
sial since its consumption has been associated with lower incidence
of Parkinson’s disease and Alzheimer’s disease,19 and also with pro-
tection against ulcerative colitis.20
Since classical tobacco cigarettes and waterpipe both burn tobacco,
similar toxic compounds are produced. Most important classes of
toxic compounds in tobacco-derived smoke are nitrosamines and
polycyclic aromatic hydrocarbons. These two groups of compounds
are known carcinogens and have been associated with many other
complications including CVD.21,22 Tobacco specific nitrosamines have
also been found in nicotine containing e-cigarette vapour.
E-cigarette liquid contains only nicotine, propylene glycol, and gly-
cerine. Accordingly, most of the toxic compounds found in e-cigar-
ette vapour are derived from the three ingredients. The main group
of toxic compounds responsible for the observed health effects of e-
cigarettes are carbonyl compounds. Toxic aldehydes and ketones
that are generated as degradation products during heating of e-cigar-
ette liquid have known negative health effects. Most notably, formal-
dehyde and acrolein exhibit their toxicity through adduct formation
with proteins and DNA, causing oxidative stress and endoplasmic re-
ticulum stress, mitochondrial dysfunction and inflammation.23
Other groups of toxic compounds found in both tobacco cigarette/
waterpipe smoke and e-cigarette vapour are volatile organic com-
pounds and inorganic compounds such as metals and carbon monoxide
(CO). Carbon monoxide is a gaseous compound that is produced as a
result of incomplete combustion of organic matter. Carbon monoxide
is toxic to humans since it can irreversibly bind to haemoglobin and in-
hibit oxygen delivery and causes hypoxia.24 Although CO is toxic to
humans, even at low concentrations, it is also an intrinsic signalling mol-
ecule produced by mammalian cells, with roles in vasodilation, regula-
tion of leucocyte aggregation (anti-atherosclerotic effect), and
reduction of ischaemia/reperfusion injury.25 Carbon monoxide can also
play a role in ischaemic preconditioning, which could be one of the ex-
planation for the ‘smoker’s paradox’.26 Since the effects of CO on the
cardiovascular system are numerous and contradictory and have been
explored before,27 we only summarized the main facts here and pro-
vide some more details in the Supplementary material online.
All of these compounds have known toxic effects on the human
body including, but not limited to, inflammation, cancer, CVD, and
impairment of cognitive ability.27–30
Details on the legal regulations of these toxic compounds as well
as the selection criteria for the inclusion of literature on toxic com-
pounds in tobacco smoke and e-cigarette vapour (Supplementary
material online, Tables S1 and S2) can be found in the Supplementary
material online.
Comparison of smoking/vaping
patterns for tobacco cigarette,
e-cigarette, and waterpipe
Smoking (puffing) topography is a set of parameters that describes
how frequently and with what volume a person inhales during
smoking. Smoking topographies of tobacco cigarette, e-cigarette, and
waterpipe users are described in Table 2. When consuming their pre-
ferred device, users exhibit very different smoking topographies.
Since puffing topography is an indirect method of determining expos-
ure to smoke or vapour, the higher puff volumes and more frequent
puffs observed in e-cigarette and waterpipe user could potentially in-
crease the exposure to toxicants.33
Smoking/vaping and
cardiovascular events
Over the last several decades, an undeniable body of evidence has
emerged demonstrating the causal association between tobacco cigar-
ette smoking and cardiovascular events including coronary heart dis-
ease, myocardial infarction, stroke, heart failure, and cardiovascular
mortality.35 The relationship between tobacco cigarette smoking and
CVD was first established in large epidemiological studies, in particu-
lar, the British Doctors Study36 and the Framingham Heart Study.37
These studies and the following examples provide evidence of a signifi-
cant contribution of cigarette smoking on major atherosclerotic CVD
outcomes and mortality. In the INTERHEART multicentre case–con-
trol study with 27 089 participants from 52 countries current smoking
was associated with a higher risk of non-fatal acute myocardial infarc-
tion [odds ratio (OR) 2.95, 95% confidence interval (CI) 2.77–3-14]
when compared with never smoking.38 The ARIC study showed
(N = 13 355) over a median follow-up of 26 years a dose–response re-
lationship between pack-years of smoking and the incidence of periph-
eral artery disease, coronary heart disease, and stroke.39 A meta-
analysis of the association of cigarette smoking with cardiovascular
mortality, including prospective studies from 25 cohorts (N = 503 905),
found a hazard ratio of 2.07 (95% CI 1.82–2.36) and 1.37 (95% CI 1.25–
1.49) for current and former smokers, respectively.40 Risk estimates in
this study for acute coronary and stroke events followed a similar pat-
tern. Also epigenetic changes may represent valuable risk markers in
smokers as lower F2RL3 methylation was strongly related to higher
mortality among a cohort of smokers with stable coronary heart dis-
ease41 (for more details see Supplementary material online).
Moreover, there is extensive evidence on the association between
chronic waterpipe smoking and cardiovascular health.42 A recent sys-
tematic review and meta-analysis revealed an OR of 1.67 (95% CI
1.25–2.24) for the association of prevalent cardiovascular conditions
such as ischaemic heart disease and heart failure with waterpipe
smoking.43 In general, adverse cardiovascular effects of long-term
waterpipe smoking are comparable to those associated with tobacco
cigarette smoking, showing that chronic use exceeding 40 waterpipe-
years is associated with a three-fold increase in the odds of coronary
artery stenosis.44 Moreover, in a large prospective study
(N = 20 033) from Bangladesh waterpipe smoking was shown to be
associated with increased risk of death due to ischaemic heart disease
in both men and women.45 More evidence for the adverse effects of
waterpipe smoke on the heart was summarized in ref.46
Although there is a broad range of evidence for the adverse acute
effects of e-cigarettes and their toxic properties on the cardiovascu-
lar system including oxidative stress and endothelial dysfunction,47
studies concerning the long-term use of e-cigarettes and CVD risk
are limited and controversial. A large study based on cross-sectional
Smoking, vaping, endothelial function, and clinical outcomes 5
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that some days use of e-cigarettes was associated with increased risk
of myocardial infarction (OR 2.11, 95% CI 1.14–3.88) after adjust-
ment for other cardiovascular risk factors.48 However, no statistically
significant association was observed in the pooled analysis (daily e-cig-
arette use: OR 1.35, 95% CI 0.80–2.27, P = 0.267). Likewise, another
study found daily e-cigarette use to be independently associated with
increased odds of myocardial infarction (OR 1.79, 95% CI 1.20–2.66),
as it was the case for daily tobacco cigarette smoking (OR 2.72, 95%
CI 2.29–3.24).49 In contrast, former and some days use of e-cigarettes
were not significantly associated with higher probability of myocardial
infarction. In addition, a recent longitudinal study established an inde-
pendent association between former and current e-cigarette use and
incident respiratory disease after adjustment for tobacco cigarette
smoking, demographic, and clinical variables.50 However, a recent
systematic review and meta-analysis concluded that despite the ad-
verse acute effects of e-cigarettes on heart rate, systolic, and diastolic
blood pressure, benefits may occur concerning blood pressure regu-
lation when switching from tobacco to chronic e-cigarette use.51
In line with this, a previous experimental study demonstrated that
there was a significant improvement of endothelial function and vas-
cular stiffness within 1 month of switching from tobacco to e-ciga-
rettes in healthy smokers, whereas no clear trend in systolic blood
pressure and heart rate was observed.52 This finding indicates that
switching to e-cigarettes may reduce the CVD burden in former to-
bacco cigarette smokers. It is important to note that the majority of
....................................................................................................................................................................................................................
Table 2 Schematic construction of tobacco cigarette, e-cigarette, and waterpipe with their corresponding puffing
topographies
Tobacco cigarette Waterpipe E-cigarette
Tobacco cigarette users display very little
deviation in their smoking topography.31
This allowed for a standardized smoking
protocol to be implemented in the form
of an ISO 3308 standard (2 s puff dur-
ation, 35 mL puff volume, and 60 s dur-
ation between puffs). An average
smoker consumes roughly between 10
and 20 cigarettes per day.
Waterpipe users usually attend only one
smoking session per day which lasts for
approximately 1 h. Puff volume, duration,
and puffing frequency are all higher in
waterpipe users in comparison to to-
bacco cigarette users. There is no ISO
standard for waterpipe smoking, but most
of the research groups use the ‘Beirut’
protocol (2.6 s puff duration, 530 mL puff
volume, and 17 s duration between
puffs).32
E-cigarette users show a much more pro-
nounced deviation in puffing parameters,
making a standard vaping protocol hard
to design.33,34 In 2019, an ISO 20768
standard was developed for routine ana-
lytical vaping experiments (3 s puff dur-
ation, 55 mL puff volume, and 30 s
duration between puffs).
6 T. Münzel et al.
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e-cigarette users are former smokers or dual users and that the avail-
ability of e-cigarettes may also promote the risk of smoking initiation
in never smokers.53 Moreover, the potential efficacy of e-cigarettes
as a cessation tool remains unclear. In a recent randomized trial
(N = 886) evaluating different smoking cessation approaches, the 1-
year abstinence rate in the e-cigarette group was 18.0% when com-
pared with 9.9% in the nicotine replacement group.54 Among suc-
cessful quitters, 80% of subjects in the e-cigarette group continued to
use them a year later, compared to only 9% in the nicotine replace-
ment group indicating that although the use of e-cigarettes was su-
perior in terms of smoking cessation, quitting nicotine products was
largely achieved in the nicotine replacement group.
Evidence of the association
between smoking/vaping tobacco
cigarette, e-cigarette, and
waterpipe on vascular/endothelial
function
A variety of different techniques have been employed to study the
vascular consequences of smoking. Evidence for tobacco cigarette
smoking-induced endothelial dysfunction and vascular damage stems
from an array of studies, whereas data on the consequences of
waterpipe and e-cigarette use are rather limited. Between and within
these studies large differences in results may occur due to a variety of
reasons such as differences in methods of measurements, time of as-
sessment post-exposure, analysed populations, used tobacco/vaping
products, and the amount and duration of inhaled smoke/vapour.
Thus, difficulties in drawing absolute conclusions may arise, demand-
ing caution in interpreting results. Here, a brief overview of the find-
ings shall be provided. Supplementary material online, Table S3
summarizes selected studies to date that have provided insights on
vascular/endothelial effects of smoking/vaping exposure.
Tobacco cigarettes
As mentioned before, Celermajer et al.9 provided early evidence that
pack-years of smoking were dose-dependently associated with
impaired FMD of the brachial artery. Likewise, long-term smoking
was also associated with impaired endothelium-dependent coronary
vasodilation.55 Importantly, decreased FMD of the brachial artery in
chronic smokers was shown to increase by 1% after 1 year of smok-
ing cessation.56 Impaired FMD was even measured in chronic smok-
ers of light cigarettes (5.59%), showing no significant difference
compared to chronic regular cigarette smokers (6.26%).57
Furthermore, smoking a single cigarette, irrespective of type,
impaired FMD in chronic smokers, indicating analogous chronic, and
acute effects. The association between exposure to second-hand
smoke and FMD was assessed in further clinical studies revealing
strong effects. Dose-dependent impairment of FMD in healthy young
subjects in response to second-hand smoke exposure was
reported,58 that may be reversible as demonstrated by a subsequent
cross-sectional study.59 In that study, FMD in former and current pas-
sive smokers was significantly impaired when compared to non-
smoking controls, while former passive smokers (5.1%) displayed
better FMD than current passive smokers (2.3%).
Heitzer et al.60 provided first evidence for the contribution of ROS
formation and dysfunctional uncoupled eNOS in the pathogenesis of
smoking-induced atherosclerosis. The authors showed that smoking
strongly enhances endothelial dysfunction in patients with the cardio-
vascular risk factor hypercholesterolaemia and that the antioxidant
vitamin C almost completely reversed endothelial dysfunction in
chronic smokers, pointing to a crucial role of ROS in the decreased
vascular NO bioavailability of endothelial dysfunction. The eNOS co-
factor tetrahydrobiopterin (BH4, cofactor of eNOS), but not NH4
(tetrahydroneopterin)61 was associated with improved vasodilation
in response to acetylcholine (Figure 2A), pointing to eNOS as a signifi-
cant superoxide source in chronic smokers. In the ALSPAC study
(n = 1266 teenagers) cigarette and alcohol use during adolescence
showed additive cardiovascular health risk.64
Waterpipe smoke
Several harmful substances present in tobacco cigarette smoke are
also present in waterpipe smoke, even exceeding those established in
cigarette smoke. Importantly, a recent statement from the American
Heart Association (AHA) concluded that the acute cardiorespiratory
toxicity of a single session of waterpipe smoking is worse than smok-
ing a single tobacco cigarette due to the significantly higher levels of
cardiorespiratory toxicants such as heavy metals and particulate mat-
ter.65 This is particularly concerning as there are general mispercep-
tions about waterpipe smoke’s addictive potential and adverse health
effects including that a majority of users believe it is less harmful and
addictive than tobacco cigarette smoking.65 In addition to changes in
cardiac function and blood pressure regulation as seen for tobacco
cigarette smoking, a 30-min waterpipe smoking session in healthy
young smokers was associated with increased vascular resistance and
decreased forearm blood flow.66 These results were later extended
to subjects with lower physical activity and fitness level exhibiting
heightened vascular responses, probably due to the lack of beneficial
effects of physical activity on endothelial function.67 In contrast, 30-
min acute exposure to waterpipe smoke was not associated with
changes in microvascular endothelial function using the Endo-PAT
technique, which may indicate differences in the pathophysiological
characteristics of endothelial dysfunction between circulatory beds.68
Smoking electrically heated waterpipe, similar to tobacco ciga-
rettes, acutely impaired FMD (-27%), whereas smoking charcoal
heated waterpipe led to increased FMD (Figure 2B).62 The authors
concluded that the acute endothelial dysfunction was masked by the
potent vasodilator CO, generated by the combustion of charcoal. A
case–control study of healthy subjects comparing endothelial func-
tion in users of chronic tobacco cigarettes vs. waterpipes vs. non-
users showed that chronic waterpipe use (7.9%) was more detrimen-
tal to FMD than cigarette use (12%) compared to non-smoking
(21.5%). These findings may be explained by differences in the
amount of exposure since most waterpipe users smoked three to
five sessions per day, while the number of cigarettes smoked per day
was 10–20 for more than 5 years.69 These findings are to be con-
trasted to a subsequent study that observed that chronic waterpipe
and cigarette smoking caused a similar worsening of FMD as well as
similar alterations of C-reactive protein levels.70
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Figure 2 Effects of different forms of smoking and vaping on endothelial function in human subjects and antioxidant interventions. (A) Left, Vitamin C
treatment markedly improves endothelium-dependent vasodilation to acetylcholine in chronic smokers while having no significant effect on the dose–
response curve of control subjects. Mean ± SEM responses of forearm blood flow to intra-arterial acetylcholine in control subjects (n = 10) and chron-
ic smokers (n = 10) with and without concomitant administration of vitamin C. *Significant difference in the overall dose–response relationship com-
pared with control subjects with and without vitamin C and with smokers with vitamin C. Adopted from ref.60 with permission of the publisher.
Copyright VC 2000, Wolters Kluwer Health. Right, Effect of BH4 on ACh-induced vasodilation in chronic smokers. BH4 significantly improved ACh-
mediated vasodilation in chronic smokers but failed to change the ACh dose–response relationship in control subjects (not shown). Data are pre-
sented as mean ± SEM. *Significant differences in the overall dose–response vs. saline treatment. Adopted from Ref.61 with permission of the publisher.
Copyright VC 2000, Wolters Kluwer Health. (B) Left, Individual and mean percentage changes before and after 30 minutes of charcoal-heated hookah
smoking. Middle, Individual and mean percentage changes before and after 30 min of electrically heated hookah smoking. Right, Individual and mean per-
centage changes before and after smoking 1 cigarette. The circles with bars reflect the overall mean ± SEM. *P < 0.05 (pre- vs post-exposure). FMD
indicates flow-mediated dilation. Adopted from ref.62 with permission of the publisher. Copyright VC 2000, Wolters Kluwer Health. (C) Systolic BP
(Left) and PWV (Right) responses. Each line represents response defined as net TC/EC smoking effect minus sham procedure effect at each time point.
BL means baseline; NS means non-significant. The P-values refer to the composite effect of TC/EC at 5 and 30 min vs. sham during the whole study dur-
ation. The composite effect of TC/EC vs. sham was determined by using mean pressure as covariate. *TC vs. sham, ¶EC at 5 min vs. sham, †EC at
30 min vs. sham, **P < 0.001, PWV change between EC 5 min session and sham session after 15 min smoking using the Student’s t-test for paired meas-
ures. Adopted from ref.63 with permission of the publisher. VC 2016 by the American College of Cardiology Foundation.
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E-cigarettes
While studies providing evidence for effects of long-term e-cigarette
use on endothelial function are generally limited, more studies evalu-
ating their short-term consequences have been conducted.
Importantly, difficulties in drawing absolute conclusions based on cur-
rent evidence arise from a variety of different approaches used in
studies including differences in methods of endothelial function meas-
urement, study population, device voltage, liquid composition (nico-
tine content and flavouring), and the amount and duration of vapour
inhaled. However, the potential harmful effects of e-cigarette use are
widely acknowledged as outlined in a recent editorial by Eissenberg
et al.3 that also called for adequate evaluation of the current evidence
on the harms of e-cigarettes. In agreement with this, a recent system-
atic review and meta-analysis concluded that e-cigarettes should not
be labelled as a safe product with respect to the cardiovascular sys-
tem, in part due to the evidence linking e-cigarettes to impaired
endothelial function.51
One study compared the acute impact of tobacco vs. e-cigarettes
with same nominal nicotine content in healthy smokers and non-
smokers on endothelial function, •NO bioavailability, markers of oxi-
dative stress, and vitamin E levels. Both tobacco and e-cigarettes
were shown to increase markers of oxidative stress and to decrease
FMD, •NO bioavailability, and vitamin E levels in smokers and non-
smokers, displaying no significant difference between tobacco and e-
cigarettes.71 Our previous work demonstrated that short-term e-cig-
arette use in healthy smokers caused marked impairment of endothe-
lial function and an increase in arterial stiffness.72 Others
demonstrated acute microvascular endothelial dysfunction measured
by acetylcholine-mediated vasodilation in smokers along with
increased markers of oxidative stress and arterial stiffness after ex-
posure to e-cigarettes with nicotine, but not after e-cigarettes with-
out nicotine.73 A similar impairment of vascular compliance was
observed following acute tobacco or e-cigarette use in smokers
(Figure 2C),63 while a study of women smokers found a significant dif-
ference in stiffness after smoking just one tobacco cigarette, but not
after use of e-cigarettes.74 In healthy seldom smokers, 10 puffs of e-
cigarette vapour inhalation caused an increase in circulating endothe-
lial progenitor cells measured by flow cytometry, qualitatively analo-
gous to the changes seen after smoking one tobacco cigarette.75 A
recent study comparing the acute effects of heat-not-burn devices, e-
cigarettes, and tobacco cigarettes in healthy smokers revealed that
single use of any product was associated with impaired FMD where
heat-not-burn and e-cigarettes were equally less harmful than to-
bacco cigarettes.76
Evidence on adverse effects of smoking/
vaping on endothelial function from
animal studies Table S4
Prolonged exposure to tobacco cigarette smoke impaired
acetylcholine-dependent vascular relaxation and coronary blood
flow in rats that was associated with increased plasma cholesterol
levels. Two weeks of tobacco cigarette smoke exposure caused mild
hypertension and endothelial dysfunction in mice by down-regulation
of sirtuin-3 and increased mitochondrial ROS formation that was
improved by overexpression of mitochondria-targeted catalase.77
Chronic cigarette smoking (up to 32 weeks) also decreased NO•
bioavailability and caused cardiac remodelling in mice that was also
associated with structural damage of the endothelium. Genetic dele-
tion of the detoxifying enzyme glutathione-S-transferase in mice
aggravated tobacco smoking-induced endothelial dysfunction and
increased acrolein-protein-adduct formation. Exposure of rabbits to
chronic passive smoking for several weeks impaired endothelium-
dependent relaxation of isolated rabbit arteries and caused left ven-
tricular hypertrophy, but did not affect neurogenic contractions. Also
mainstream smoke exposure of rabbits for several weeks impaired
endothelial function of vascular tissues that was either corrected by
ascorbic acid therapy or aggravated by a hypercholesterolaemic diet.
As indicated by our own results, e-cigarette vapour exposure (up
to 5 days) caused endothelial dysfunction of isolated aortic segments
of exposed mice that was associated with cardiovascular and cerebral
oxidative stress, eNOS uncoupling, NOX-2 activation, endothelin-1
expression, as well as acrolein-adduct formation.72 These adverse
effects were corrected by the endothelin-receptor blocker maciten-
tan and genetic Nox2 deletion, as well as pharmacological NOX-2 in-
hibition. Studies on endothelial function in various animal models
suggest comparable effects on smoking- or vaping-induced endothe-
lial dysfunction. Also, chronic exposure of mice to e-cigarette vapour
or tobacco smoke for 8 months induced a similar degree of arterial stiff-
ness or endothelial dysfunction in isolated vessels (Figure 3A and B).78
Acute exposure of rats to the vapour of high nicotine containing
e-cigarette liquid (JUUL), normal nicotine containing e-cigarette
liquid, or traditional tobacco smoke (Marlboro red) resulted in
similar decrease in endothelial function (Figure 3C and D).79,80 The
nicotine uptake was measured by serum cotinine levels and corre-
lated with FMD.
In summary, animal data suggest very similar extent of endothelial
dysfunction by e-cigarette vaping or tobacco smoking, with oxidative
stress and inflammation as central players of this process (Figure 4).
These data are also in accordance with previous reviews on tobacco
cigarette smoking,82 waterpipe smoking,42,83 and e-cigarette vap-
ing.47,84,85 More details on the molecular mechanisms (e.g. the inter-
play of toxic compounds, oxidative stress and inflammation as well as
epigenetic/circadian regulations) of the induction of endothelial dys-
function by e-cigarette vaping or tobacco smoking can be found in
the Supplementary material online (summarized in Supplementary
Table S4). Epigenetic regulations (e.g. via sirtuin-1) may also negative-
ly affect endothelial function and life span of smokers, e.g. by activa-
tion of the mitochondrial adaptor protein p66Shc and subsequent
mitochondrial dysfunction and oxidative stress.86
Recommendations/regulatory
updates for tobacco, e-cigarette,
and waterpipe smoking
Most of the countries in the world have implemented some form of
tobacco products regulation. In the USA, the FDA regulates all
aspects of tobacco production and sales. In 2016, FDA has included
waterpipe and e-cigarettes into the list of tobacco products, so they
are regulated the same way as tobacco cigarettes. Although FDA
allows sales of e-cigarettes, some organizations within the USA have
called for their total ban. The Center for Disease Control (CDC)
Smoking, vaping, endothelial function, and clinical outcomes 9
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Figure 3 Chronic and acute effects of different forms of smoking and vaping on endothelial function in animals. (A) B-mode Doppler ultrasound
in vivo data from the carotid artery of mice under anaesthesia (inhaled isoflurane) before, during (at 4.5 months), and after 8 months of chronic
10 T. Münzel et al.
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recommends that e-cigarettes of all kinds ‘never be used by youths’87
and the WHO expressed reservations about the value of e-cigarettes
and grave concerns about their risks.88 The AHA has started a cam-
paign to ban all e-cigarette sales.89 The AHA claims that there is
enough evidence associating e-cigarettes with teenager’s addiction to
nicotine and with seduction of non-smokers to smoking. A recent
‘epidemic’ of lung injury, and even deaths, resulting from use of e-ciga-
rettes has caught attention of many health organizations.90 Although
the majority of the reported cases of lung injury have been associated
with use of e-cigarettes for THC consumption as well as vitamin E
additives, the CDC has responded by recommending that people
should avoid vaping altogether.91
Countries belonging to the WHO Framework Convention on
Tobacco Control (FCTC—181 countries, excluding USA) have all
agreed that they will implement the recommended guidelines on pro-
tection of public health policies, protection from exposure to to-
bacco smoke, regulation of tobacco products, advertising, sales, and
also for reduction measures concerning tobacco dependence and
cessation.92 The WHO does not have the power to create laws, but
most of its member countries have implemented their recommenda-
tions to some extent. In the European Union (EU), tobacco products
and smoking are heavily regulated. In most countries, there is a ban
on smoking in the workplace and enclosed public spaces. Some coun-
tries (such as Hungary, UK, and Ireland) have a total ban on smoking
in bars and hotels, while other countries (such as France, Germany,
and Italy) allow for a designated smoking area in bars and hotels.
Some countries have even banned smoking in outdoor areas near to
hospitals, children’s playgrounds, and bus stops.93
Nevertheless, the position of Europe in particular with respect to
e-cigarettes is not consistent at all. In the UK, the National Health
Service (NHS) and the British Heart Foundation (BHF) strongly sup-
port the use of e-cigarettes in order to quit tobacco smoking.
According to a 2019 YouGov survey,94 more than 3.6 million adults
in Great Britain use e-cigarettes 7.1% of the adult population. Of
these users, 54% are ex-smokers, suggesting they are trying to stop
smoking. It is proposed that it might be easier to quit with an e-cigar-
ette. They also recommend that any smoker with a heart condition
should try e-cigarettes in case he has tried to quit in the past, and
failed. They propose that it might be a lot easier to quit smoking with
an e-cigarette although they are probably not completely safe.
Waterpipe is considered a tobacco product in most countries and
it also has to follow the no-smoking laws and regulations. Waterpipe
bars are prohibited in some countries but can operate in others. Some
countries have specific regulations for smoking establishments (usually
no food or drinks can be served), and some treat them as regular
smoking areas within a bar. E-cigarettes have been legally recognized
as tobacco products in most countries, although individual countries
regulate them differently. In some countries that ban indoor smoking
(such as UK and Ireland), e-cigarettes could be used to circumvent no-
smoking laws, since the ban does not apply to them. According to the
2019 report from the Global Center for Good Governance in
Tobacco Control (GGTC), e-cigarette sales are banned in 42 coun-
tries and regulated in 56 countries.95 The sales regulation by country is
shown in Figure 5A. The 42 countries that have banned e-cigarette
sales, represent 35% of the world population with another 35% living
in the countries where sales are regulated. Some countries, such as
Turkey, have issued a statement that they will completely ban all e-cig-
arette sales, but haven’t done so at the present.
Advertising
In the EU, TV and radio advertising of cigarettes, and tobacco prod-
ucts is not permitted. Some countries (such as Slovenia and Norway)
have strict laws that ban all types of advertising, even at the place of
sale. Germany is unfortunately the only EU country where tobacco
products, including e-cigarettes, can be advertised in public spaces via
billboards. Also in the US advertising of both tobacco products and
e-cigarettes through the medium of billboards is allowed. E-cigarettes
are mostly considered as tobacco products, but the regulations on
their advertising are not always clear. The map of Europe shows in
which country advertising of e-cigarettes is legal (Figure 5B).
Impact of coronavirus disease 2019
(COVID-19) on cardiovascular risk
in smokers and vapers
Recently, evidence has emerged indicating that tobacco use may in-
crease the risk of adverse health outcomes in coronavirus disease
Figure 3 Continued
exposure to electronic cigarette (E-cig) vapour and reference tobacco (3R4F) cigarette smoke. Left: significant increase in arterial stiffness
[measured as pulse wave velocity (PWV)] for E-cig and 3R4F groups following 8-month exposure. Right: significantly greater change in PWV
(translating to greater arterial stiffness) after 8 months in E-cig- and 3R4F-exposed than control (air-exposed) mice. Slight, non-significant, rise
in PWV in control mice following 8 months is consistent with the normal aging effect. n = 5–8 mice/group. *P < 0.05 vs. air. (B) Ex vivo dose–re-
sponse curves for phenylephrine (Left) and methacholine (Right), obtained from thoracic aorta ring segments following 8 months of exposure
to E-cig vapour, reference tobacco (3R4F) cigarette smoke, and filtered air. a-Adrenergic vasoconstrictor response was greater (Left), while
the endothelium-mediated vasodilatory response was impaired (Right), following 8 months of exposure to E-cig vapour and 3R4F cigarette
smoke. Response to sodium nitroprusside was not altered or different between groups (not shown). n = 5 mice/group. *P < 0.05 vs. air.
Adopted from ref.78 with permission of the publisher. Copyright VC 2018, The American Physiological Society. (C) FMD was impaired by acute
exposure to JUUL aerosol, previous generation e-cig aerosol, and Marlboro Red cigarette smoke. FMD after 5 min of exposure is shown.
Coloured lines denote individual rats. Horizontal black bars denote the mean of the respective groups. P-values are derived from paired two-
tailed t-tests. (D) Serum levels (ng/mL) of nicotine and cotinine from sera collected after 20 min of exposure. *P < 0.001 compared to air
group. §P < 0.001 compared to JUUL. ‘Previous Gen’ means previous generation. Adopted from ref.79 Permission granted by Tobacco
Regulatory Science Group to use figures. Rao P, Liu J, Springer ML. JUUL and combusted cigarettes comparably impair endothelial function.
Tob Regul Sci 2020;6:30-37.
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Figure 4 Effects of different forms of smoking and vaping as summarized from human and animal studies. The major toxicants (red, blue and green
= high quantity, black = intermediate quantity, grey = trace amounts) for tobacco cigarette and waterpipe smoking as well as e-cigarette vaping are
listed. The molecular link of these toxicants on major damage markers reported for the different forms of smoking and vaping with respect to oxida-
tive stress is shown on the left side. The effects of these toxicants on endothelial (vascular) function are summarized in the inserted scheme (modified
from ref.81 with permission). The associated adverse health effects as well as antioxidant interventions are also shown.
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..2019 (COVID-19) patients. As outlined by the WHO, tobacco cigar-
ette and waterpipe smoking may contribute to increased burden of
symptoms due to COVID-19 compared to non-smoking, including
being admitted to intensive care, requiring mechanical ventilation,
and suffering severe health consequences.96 Since smoking per se is a
well-established risk factor for respiratory infections and increases
the probability of having pre-existing conditions such as CVD, it could
make COVID-19 patients more susceptible to severe symptoms,
thus leading to increased mortality. Accordingly, considering the po-
tential acute pulmonary and cardiovascular toxicity of e-cigarettes,
the use of these products may put patients at higher risk of severe ill-
ness from COVID-19.97 As a potential mechanistic basis for COVID-
Figure 5 Overview on global regulations on e-cigarette products sales (A) and on European regulations on tobacco product advertising (B). Maps
were created using data from www.globaltobaccocontrol.org, www.tobaccocontrollaws.org and https://ggtc.world (last accessed 31/05/2020).
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19 associated cardiovascular complications, recent data by electron
microscopy revealed viral inclusion structures in endothelial cells
leading to endotheliitis that was associated with an accumulation of
inflammatory cells in the endothelium as well as apoptotic bodies in
the heart,98 with the consequence of impaired microcirculatory func-
tion. The authors explain that severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infects the host using the angiotensin-
converting enzyme 2 (ACE2) receptor, which is expressed in several
organs, including the lung, heart, kidney, and the intestine. Of note,
ACE2 is also expressed by endothelial cells.99 Thus, the endothelium
should be targeted with antiviral substances and cardiovascular drugs
with anti-inflammatory pleiotropic effects such as angiotensin-
converting enzyme inhibitors and statins. In addition, this therapeutic
strategy may be implemented mainly in subjects with already existing
endothelial dysfunction due to male sex, smoking, hypertension, dia-
betes, obesity, and established CVD, all of which are associated with
adverse outcomes in COVID-19.98
Conclusions, clinical implications
and gaps in current knowledge
Taken together, there is no doubt tobacco cigarette smoke has se-
vere cardiovascular side effects leading to endothelial dysfunction,
increased oxidative stress, and increased cardiovascular morbidity
and mortality. There is also evidence that e-cigarette vapour is less
toxic than tobacco smoke. Nevertheless, acute e-cigarette smoking
increases blood pressure, causes endothelial dysfunction and
increases vascular and cerebral oxidative stress. Despite being less
toxic, the proposed 95% less harmful assertion by the Public Health
England and the Royal College of Physician should be rapidly re-
evaluated due to the growing body of hard evidence regarding harm
caused by e-cigarettes. Waterpipe smoking is not less harmful than
tobacco smoking and thus cannot be considered a healthy alternative.
Hookah smoke has significant cardiovascular side effects, causes
endothelial dysfunction, oxidative stress within the vasculature and
arterial hypertension. The greater smoke volumes expelled from
waterpipe sessions may lead to even higher exposure to toxicants as
compared to tobacco cigarette smoking. In general, the increased use
of e-cigarettes and waterpipe is concerning and as recently recom-
mended broader tobacco control efforts by raising tobacco taxes,
adopting smoke-free laws, conducting mass media campaigns, and
restricting tobacco marketing should be implemented for better
health protection of the general population.100 Future research
should focus in particular on the long-term adverse effects of e-cigar-
ette and waterpipe smoking on the cardiovascular system or respira-
tory diseases and cancer, as strong evidence is still missing
(summarized in Figure 1). In particular, individuals exposed to second-
hand smoke will benefit from any increased knowledge concerning
the impact on CVD from tobacco/waterpipe (shisha) and e-cigarette
smoking/vaping. There is no doubt, however, that smoking cessation
is and will remain the most powerful approach to prevent smoking-
induced cardiovascular and respiratory disease.101 This may be even
more important in light of the actual COVID-19 pandemic as it
increases the risk for COVID-19 associated cardiovascular and other
severe complications in smokers and vapers.
Supplementary material
Supplementary material is available at European Heart Journal online.
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Lundbäck M. Electronic cigarettes increase endothelial progenitor cells in the
blood of healthy volunteers. Atherosclerosis 2016;255:179–185.
76. Biondi-Zoccai G, Sciarretta S, Bullen C, Nocella C, Violi F, Loffredo L, Pignatelli
P, Perri L, Peruzzi M, Marullo AGM, De Falco E, Chimenti I, Cammisotto V,
Valenti V, Coluzzi F, Cavarretta E, Carrizzo A, Prati F, Carnevale R, Frati G.
Acute effects of heat-not-burn, electronic vaping, and traditional tobacco com-
bustion cigarettes: the Sapienza University of Rome-Vascular Assessment of
Proatherosclerotic Effects of Smoking (SUR - VAPES) 2 randomized trial. J Am
Heart Assoc 2019;8:e010455.
77. Dikalov S, Itani H, Richmond B, Arslanbaeva L, Vergeade A, Rahman SMJ,
Boutaud O, Blackwell T, Massion PP, Harrison DG, Dikalova A. Tobacco smok-
ing induces cardiovascular mitochondrial oxidative stress, promotes endothelial
dysfunction, and enhances hypertension. Am J Physiol Heart Circ Physiol 2019;
316:H639–H646.
78. Olfert IM, DeVallance E, Hoskinson H, Branyan KW, Clayton S, Pitzer CR,
Sullivan DP, Breit MJ, Wu Z, Klinkhachorn P, Mandler WK, Erdreich BH,
Ducatman BS, Bryner RW, Dasgupta P, Chantler PD. Chronic exposure to
electronic cigarettes results in impaired cardiovascular function in mice. J Appl
Physiol (1985) 2018;124:573–582.
79. Rao P, Liu J, Springer ML. JUUL and combusted cigarettes comparably impair
endothelial function. Tob Regul Sci 2020;6:30–37.
80. Nabavizadeh P, Liu J, Havel CM, Ibrahim S, Derakhshandeh R, Jacob Iii P,
Springer ML. Vascular endothelial function is impaired by aerosol from a single
IQOS HeatStick to the same extent as by cigarette smoke. Tob Control 2018;27:
s13–s19.
81. Munzel T, Sorensen M, Gori T, Schmidt FP, Rao X, Brook FR, Chen LC, Brook
RD, Rajagopalan S. Environmental stressors and cardio-metabolic disease: part
II-mechanistic insights. Eur Heart J 2017;38:557–564.
82. Messner B, Bernhard D. Smoking and cardiovascular disease: mechanisms of
endothelial dysfunction and early atherogenesis. Arterioscler Thromb Vasc Biol
2014;34:509–515.
83. Golbidi S, Li H, Laher I. Oxidative stress: a unifying mechanism for cell damage
induced by noise, (water-pipe) smoking, and emotional stress-therapeutic strat-
egies targeting redox imbalance. Antioxid Redox Signal 2018;28:741–759.
84. Morris PB, Ference BA, Jahangir E, Feldman DN, Ryan JJ, Bahrami H, El-Chami
MF, Bhakta S, Winchester DE, Al-Mallah MH, Sanchez Shields M, Deedwania P,
Mehta LS, Phan BA, Benowitz NL. Cardiovascular effects of exposure to cigar-
ette smoke and electronic cigarettes: clinical perspectives from the prevention
of cardiovascular disease section leadership council and early career councils of
the American College of Cardiology. J Am Coll Cardiol 2015;66:1378–1391.
85. Buchanan ND, Grimmer JA, Tanwar V, Schwieterman N, Mohler PJ, Wold LE.
Cardiovascular risk of electronic cigarettes: a review of preclinical and clinical
studies. Cardiovasc Res 2020;116:40–50.
86. Shi Y, Camici GG, Luscher TF. Cardiovascular determinants of life span. Pflugers
Arch 2010;459:315–324.
87. Centers for Disease Control and Prevention report. https://www.cdc.gov/to-
bacco/basic_information/e-cigarettes/severe-lung-disease/faq/index.html? CDC_
AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Ftobacco%2Fbasic_
information%2Fe-cigarettes%2Fsevere-lung-disease%2Fneed-to-know%2Findex.
html (31 May 2020).
88. WHO report. https://www.who.int/news-room/q-a-detail/e-cigarettes-how-
risky-are-they (31 May 2020).
89. American Heart Association news item. 2019. https://pace-cme.org/2019/11/16/
aha-launches-anti-e-cigarette-campaign-with-hashtag-quitlying-addressed-to-big-
vape/. (31 May 2020).
90. Layden JE, Ghinai I, Pray I, Kimball A, Layer M, Tenforde M, Navon L, Hoots B,
Salvatore PP, Elderbrook M, Haupt T, Kanne J, Patel MT, Saathoff-Huber L, King
BA, Schier JG, Mikosz CA, Meiman J. Pulmonary illness related to e-cigarette
use in Illinois and Wisconsin—preliminary report. N Engl J Med 2020;382:
903–916.
91. Centers for Disease Control and Prevention report. https://www.cdc.gov/to
bacco/basic_information/e-cigarettes/severe-lung-disease.html (31 May 2020).
92. WHO report. https://www.who.int/fctc/treaty_instruments/adopted/en/ (31
May 2020).
93. European Commission report. https://ec.europa.eu/health/tobacco/smoke-free_
environments_en (31 May 2020).
94. Action on Smoking and Health. https://ash.org.uk/wp-content/uploads/2019/09/
Use-of-e-cigarettes-among-adults-2019.pdf (31 May 2020).
95. E-cigarette ban & regulation Global Status 2019. https://ggtc.world/dmdocu
ments/E-cigarette%20ban%26regulation-Global-Status-as-of-October-2019.
pdf (31 May 2020).
96. World Health Organization. Tobacco and waterpipe use increases the risk of
suffering from COVID-19. http://www.emro.who.int/tfi/know-the-truth/to
bacco-and-waterpipe-users-are-at-increased-risk-of-covid-19-infection.html (31
May 2020).
97. Javelle E. Electronic cigarette and vaping should be discouraged during the new
coronavirus SARS-CoV-2 pandemic. Arch Toxicol 2020;doi:
10.1007/s00204-020-02744-z.
98. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS,
Mehra MR, Schuepbach RA, Ruschitzka F, Moch H. Endothelial cell infection and
endotheliitis in COVID-19. Lancet 2020;39:1417–1418.
99. Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, Diz
DI, Gallagher PE. Effect of angiotensin-converting enzyme inhibition and angio-
tensin II receptor blockers on cardiac angiotensin-converting enzyme 2.
Circulation 2005;111:2605–2610.
100. Kalkhoran S, Benowitz NL, Rigotti NA. Prevention and treatment of tobacco
use: JACC Health Promotion Series. J Am Coll Cardiol 2018;72:1030–1045.
101. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney
MT, Corra U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FDR, Lochen
ML, Lollgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar
N, Smulders Y, Tiberi M, van der Worp HB, van Dis I, Verschuren WMM,
Binno S; Group ESCSD. 2016 European Guidelines on cardiovascular disease
prevention in clinical practice: the Sixth Joint Task Force of the European
Society of Cardiology and Other Societies on Cardiovascular Disease
Prevention in Clinical Practice (constituted by representatives of 10 societies
and by invited experts)Developed with the special contribution of the
European Association for Cardiovascular Prevention & Rehabilitation (EACPR).
Eur Heart J 2016;37:2315–2381.
16 T. Münzel et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartj/article-abstract/doi/10.1093/eurheartj/ehaa460/5861975 by M
edical C
enter Library user on 08 July 2020
